Diality Inc. closes $24 million in financing for hemodialysis system
Click Here to Manage Email Alerts
Medical device developer Diality Inc. announced the close of its $24 million Series B2 investment round, according to a press release.
The release noted that dialysis delivery is becoming “decentralized” due to “rising costs and poor outcomes associated with in-center dialysis.” Diality has taken into consideration the cost of delivery for users such as non-specialty nurses, patients and care partners.
“To meet the needs of prescribing physicians and their patients in acute, sub-acute, chronic and home settings, a versatile machine also needs to be capable of delivering a wide range of dialysis prescriptions,” Osman Khawar, MD, CEO of Diality, said in the release.
“We see the lack of a machine with this level of versatility in a compact footprint as a lingering market gap that we seek to fill by bringing to market a best in-class system capable of delivering the intense dialysis doses commonly prescribed for patients receiving three dialysis treatments per week, in addition to lower-intensity doses suitable for more frequent dialysis."
The release further noted that the Series B2 round funding will be spent trying to gain 510(k) clearance from the FDA and supporting an upcoming home clinical. Additionally, Diality intends to use the funding to build a U.S. commercial organization.
Click Here to Manage Email Alerts